Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents

Alvarez Sotomayor E, Teicher BA, Schwartz GN, Holden SA, Menon K, Herman TS, Frei III E: Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 30:377–384, 1992

Teicher BA, Alvarez Sotomayor E, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702–6704, 1992

Teicher BA, Alvarez Sotomayor E, Huang ZD, Ara G, Holden S, Khandekar V, Chen Y-N: β-Cyclodextrin tetradecasulfate/tetrahydrocortisol ± minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma. Cancer Chemother Pharmacol 33:229–238, 1993

Teicher BA, Holden SA, Ara G, Alvarez Sotomayor E, Huang ZD, Chen Y-N, Brem H: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with antiangiogenic agents. Int J Cancer 57:920–925, 1994

Teicher BA, Holden SA, Dupuis NP, Kakeji Y, Ikebe M, Emi Y, Goff D: Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Ca Res Trtmt 36:227–236, 1995

Teicher BA, Dupuis NP, Robinson M, Emi Y, Goff D: Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncology Res 7(5):237–243, 1995

Teicher BA, Dupuis N, Kusomoto T, Robinson MF, Liu F, Menon K, Coleman CN: Antiangiogenic agents can increase tumor oxygenation and responses to radiation therapy. Radiat Oncol Invest 2:269–276, 1995

Brem H, Ingber D, Blood CH, Bradley D, Urioste S, Folkman J: Suppression of tumor metastasis by angiogenesis inhibition. Surg Forum 42:439–441, 1991

Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamura T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555–557, 1990

Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, Folkman J: Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 69:212–216, 1994

Antoine N, Greimers R, De Roanne C, Kusaka M, Heinen E, Simar LJ, Castronovo V: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 54:2073–2076, 1994

Yamamoto T, Sudo K, Fujita T: Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res 14:1–4, 1994

Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J: Potent antiangiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 174:1070–1976, 1991

Takayamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL: Inhibition of angiogenesis and growth of human nerve sheath tumors by AGM-1470. J Neurosurg 78:470–476, 1993

Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K: Inhibitory effect of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. Cancer Res 53:2566–2570, 1993

Kamei S, Okada H, Inoue Y, Yoshioka T, Ogawa T, Toguchi H: Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J Pharmacol Exper Ther 264(1):469–474, 1993

Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(Chloroacetylcarbamoyl)fumagillin (TNP-470; AGM-1470). Cancer Res 53:4262–4267, 1993

Toi M, Yamamoto Y, Imazawa T, Takayanagi T, Akutsu K, Tominaga T: Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int J Oncol 3:525–528, 1993

Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T: Angiogenesis inhibitor TNP-470 (AGM-470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 53:5233–5236, 1993

Schoof DD, Obando JA, Cusack Jr. JC, Goedegebuure PS, Brem H, Eberlein TJ: The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro. Int J Cancer 55:630–635, 1993

Tsujimoto H, Hagiwara A, Osaki K, Ohyama T, Sakakibara T, Sakuyama A, Ohgaki M, Imanishi T, Watanabe N, Yamazaki J, Shirasu M, Sakakura C, Shimotsuma M, Takahashi T: Therapeutic effects of the angiogenesis inhibitor TNP-470 against carcinomatous peritonitis in mice. Anti-Cancer Drugs 6:438–442, 1995

Placidi L, Cretton-Scott E, de Sousa G, Rahmani R, Placidi M, Sommadossi J-P: Disposition and metabolism of the angiogenic moderator O-(chloracetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res 55:3036–3042, 1995

Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. Cancer Res 51:672–675, 1991

Takano S, Gately S, Neville M, Herblin WF, Gross JL, Brem S: Suramin, an inhibitor of angiogenesis, suppresses endothelial cell growth, migration and plasminogen activator activity. Proc Amer Assoc Cancer Res 34:74, 1993

Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV, Myers CE, Paparelli A, Del Tacca M: Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 68:932–938, 1993

Stein CA, La Rocca RV, Thomas R, McAtee N, Myers CE: Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7:499–508, 1989

Yayon A, Klagsbrun M: Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor: reversal by suramin. Proc Nat Acad Sci USA 87:5346–5350, 1990

Firsching A, Nickel P, Mora P, Allolio B: Antiproliferative and angiostatic activity of suramin analogues. Cancer Res 55:4957–4961, 1995

Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76:453–462, 1995

Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54:2654–2660, 1994

Barnes S, Grubbs C, Setchell KDR, Carlson J: Soybeans inhibit mammary tumor in models of breast cancer. In: Pariza M, Liss AR (eds), Mutagens and carcinogens in the diet. Wiley-Liss. New York, 1990, pp 239–253

Messina M, Barnes S: The role of soy products in reducing risk of cancer. J Natl Cancer Inst 83:541–546, 1991

Wei H, Wei L, Frenkel K, Bowen R, Barnes S: Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr Cancer 20:1–12, 1993

Zwiller J, Sassone-Corsi P, Kakazu K, Boyton AL: Inhibition of PDGF-induced c-jun and c-fos expression by a tyrosine protein kinase inhibitor. Oncogene 6:219–221, 1991

Linassier C, Pierre M, Le Peco J-B, Pierre J: Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity. Biochem Pharmacol 39:187–193, 1990

Yamashita Y, Kawada S, Nakano H: Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol 39:737–744, 1990

Constantinou A, Kiguchi K, Huberman E: Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res 50:2618–2624, 1990

Kondo K, Watanabe T, Oishi M: Induction of in vitro differentiation of mouse embryonal carcinoma (F9) cells by inhibitors of toposiomerases. Cancer Res 51:5398–5404, 1991

Watanabe T, Kondo K, Oishi M: Induction of in vitro differentiation of mouse erythroleukemia cells by genistein, an inhibitor of tyrosine protein kinases. Cancer Res 51:764–768, 1991

Peterson G, Barnes S: Genistein inhibition of the growth of human breast cancer cells: independent from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 179:661–667, 1991

McCabe Jr. MJ, Orrenius S: Genistein induces apoptosis in immature human thymocytes by inhibiting toposiomerase-II. Biochem Biophys Res Commun 194(2):944–950, 1993

O'Dell TJ, Kandel ER, Grant SGN: Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors. Lett Nature 353:558–560, 1991

Kanatani Y, Kasukabe T, Hozumi M, Motoyoshi K: Genistein exhibits preferential cytotoxicity to a leukemogenic variant but induces differentiation of a non-leukemogenic variant of the mouse monocytic leukemia Mm cell line. Leuk Res 17(10):847–853, 1993

Markovits J, Junqua S, Goldwasser F, Venuat A-M, Luccioni C, Beaumatin J, Saucier J-M, Bernheim A, Jacquemin-Sablon A: Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II β isoform. Biochem Pharmacol 50(2):177–186, 1995

Supko JG, Malspeis L: Plasma pharmacokinetics of genistein in mice. Int J Oncol 7:847–854, 1995

Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Nat Acad Sci USA 90:2690–2694, 1993

Weidner N, Folkman J, Pozza F, Pierantonio B, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887, 1992

Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. New Eng J Med 324:1–8, 1991

Grunt TW, Lametschwadtner A, Karrer K: The characteristic structural feature of the blood vessels of the Lewis lung carcinoma. Scan Electron Microsc 11:575–589, 1986

Grunt TW, Lametschwadtner A, Karrer K, Staindl O: The angioarchitecture of the Lewis lung carcinoma in laboratory mice. Scan Electron Miscrosc 11:557–574, 1986

White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL: Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. Med Intell 18:1197–1200, 1989

White CW, Wolf SJ, Korones DN, Sondheimer HM, Tosi MF, Yu A: Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr 118:59–66, 1991

Nanus DM, Schmitz-Dräger BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, Albino AP, Reuter VE: Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85:1597–1599, 1993

Dickson RB, Lippman ME: Molecular determinants of growth, angiogenesis, and metastases in breast cancer. Semin Oncol 19:286–298, 1992

Aaltoma S, Lipponen P: Prognostic factors in breast cancer (review). Int J Oncol 1:153–159, 1992

Gasparini G, Gullick WJ, Bevilacqua P, Pozza F, Lemoine NR, Meli S, Boracchi P, La Malfa G, Weidner N: Pathobiological characteristics of the first primary and risk of metachronous contralateral invasive breast carcinoma: clinical implications. Int J Oncol 2:781–790, 1993

Van Hoef MEHM, Knox WF, Dhesi SS, Howell A, Schor AM: Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 29A(8):1141–1145, 1993

Teicher BA, Holden SA, Ara G, Dupuis N, Liu F, Yuan J, Ikebe M, Kakeji Y: Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer 61(5):732–737, 1995